IBC Addresses Critical Supply Shortages of Ac-225 with Commercially Available Molecular Recognition Technology™ for Highly Selective Separation of Ac-225

IBC Advanced Technologies, Inc. Utah New York

Strong clinical potential of radioligand therapy is evident from recently published clinical trial resultsGlobal supply shortage of Ac-225 is impacting supply to clinical trialsDemand is increasing for high-purity isotopes to conduct and scale up clinical studies and support regulatory approvals in the US and EuropeIBC's state-of-the-art highly selective separation technology, MRT™, for Ra-226 recovery and Ac-225 separation will help to address these issuesRa-226 and Ac-225 are separated at up to 99.99% purity and with 99.9+% recovery yieldView original content:https://www.prnewswire.co.uk/news-releases/ibc-addresses-critical-supply-shortages-of-ac-225-with-commercially-available-molecular-recognition-technology-mrt-for-highly-selective-separation-of-ac-225-302166218.html